Inzolfi

Fingolimod, the active ingredient in Inzolfi, is a sphingosine 1‑phosphate (S1P) receptor modulator presented as an oral formulation for oral use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients. GNH USA supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inzolfi is a sphingosine‑1‑phosphate receptor modulator used in the management of multiple sclerosis and related disease activity.

Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows disability progression. Active secondary progressive multiple sclerosis with relapses: delays worsening of disability. Clinically isolated syndrome at high risk of conversion: decreases the likelihood of a second clinical event.

Fingolimod may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Diarrhoea: loose stools, usually transient. - Fatigue: generalised tiredness. - Cough: dry or productive. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Herpes virus infections: reactivation risk. - Cardiac arrhythmia: bradycardia or conduction delays. - Macular edema: visual disturbances requiring ophthalmic monitoring. - Progressive multifocal leukoencephalopathy: rare opportunistic infection. - Severe liver injury: marked transaminase elevation. - Severe hypertension: significant blood pressure rise.

Before initiating therapy, clinicians should assess several safety parameters.

Baseline cardiac assessment: obtain ECG and monitor first dose for heart‑rate changes. Vaccination status: avoid live vaccines during treatment and for at least two months after discontinuation. Liver function monitoring: check transaminases periodically and adjust if significant elevation occurs. Infection risk: monitor for signs of infection and counsel patients on prompt reporting. Pregnancy considerations: discontinue therapy if pregnancy is confirmed and discuss contraception. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Fingolimod can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other S1P modulators: additive immunosuppression. - Strong CYP4F2 inhibitors: may increase fingolimod plasma concentrations. - Live attenuated vaccines: heightened risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask fingolimod‑induced bradycardia. - Antihypertensives: potential additive blood‑pressure lowering effect. - Non‑live vaccines: monitor immune response efficacy.